1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

4506.T
Sumitomo Pharma Co., Ltd.JP flagTokyo Stock Exchange
1,553.00
JPY
-4.00
- -
696.67BMarket Cap

Total Valuation

Sumitomo Pharma Co., Ltd. carries a market capitalization of 696.67B, placing it among publicly traded companies globally. Its enterprise value stands at 510.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap696.67B
Enterprise Value510.34B

Share Statistics

Sumitomo Pharma Co., Ltd. currently has 397.29M shares outstanding.

Shares Outstanding397.29M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.46, and the price-to-book ratio stands at 25.89.

PE RatioN/A
PS Ratio1.46
PB Ratio25.89
P/TBV Ratio-0.93
P/FCF Ratio-3.94
P/OCF Ratio-3.51

Enterprise Valuation

EV / Sales3.15
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Sumitomo Pharma Co., Ltd. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 340.83, indicating elevated leverage, while an interest coverage ratio of -13.86 demonstrates limited ability to service its debt obligations.

Current Ratio0.64
Quick Ratio0.24
Debt / Equity340.83
Debt / EBITDA-1.45
Interest Coverage-13.86

Financial Efficiency

Return on Equity (ROE)-198.60
Return on Assets (ROA)-25.37
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.62

Taxes

Income Tax-19.79B
Effective Tax RateN/A

Stock Price Statistics

Sumitomo Pharma Co., Ltd.'s stock has gained approximately 71.4128% over the past 52 weeks. The 50-day moving average sits at 1,564.40, while the 200-day moving average is 2,018.22.

Beta (5Y)N/A
52-Week Price Change71.4128%
50-Day Moving Average1,564.40
200-Day Moving Average2,018.22
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sumitomo Pharma Co., Ltd. generated 161.92B in revenue and converted that into -247.23B in net income, yielding earnings per share of -622.16. EBITDA reached -268.36B, while operating income came in at -268.36B.

Revenue161.92B
Gross Profit95.66B
Operating Income-268.36B
Pretax Income-266.99B
Net Income-247.23B
EBITDA-268.36B
EBIT-268.36B
Earnings Per Share (EPS)-622.16

Balance Sheet

Sumitomo Pharma Co., Ltd. holds 115.91B in cash and equivalents against 389.38B in total debt, resulting in a net debt position of 290.30B. Total book value stands at 9.15B, with working capital of -174.59B providing operational flexibility.

Cash & Cash Equivalents115.91B
Total Debt389.38B
Net Debt290.30B
Equity (Book Value)9.15B
Book Value Per Share23.02
Working Capital-174.59B

Cash Flow

Sumitomo Pharma Co., Ltd. produced -67.40B in operating cash flow over the past twelve months. After subtracting -7.29B in capital expenditures, free cash flow totaled -74.69B - equivalent to -187.98 per share.

Operating Cash Flow-67.40B
Capital Expenditures-7.29B
Free Cash Flow-74.69B
FCF Per Share-187.98

Margins

Sumitomo Pharma Co., Ltd. operates with a gross margin of 59.08, reflecting its pricing power and cost economics. The operating margin of -165.74 and net profit margin of -152.69 provide insight into operational efficiency.

Gross Margin59.08
Operating Margin-165.74
Pretax Margin-164.89
Profit Margin-152.69
EBITDA Margin-165.74

Dividends & Yields

The company's payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.02
Dividend YieldN/A
Payout Ratio0.00
Shareholder Yield-13.96
FCF Yield-25.38

Scores

Sumitomo Pharma Co., Ltd. posts an Altman Z-Score of -2.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.00